Novel, emerging and provisional renal entities: The Genitourinary Pathology Society (GUPS) update on renal neoplasia

K Trpkov, SR Williamson, AJ Gill, AJ Adeniran… - Modern …, 2021‏ - nature.com
Abstract The Genitourinary Pathology Society (GUPS) undertook a critical review of the
recent advances in renal neoplasia, particularly focusing on the newly accumulated …

What's new in the WHO 2022 classification of kidney tumours?

R Alaghehbandan, F Siadat, K Trpkov - Pathologica, 2023‏ - pmc.ncbi.nlm.nih.gov
Summary The World Health Organization (WHO) 2022 classification of urinary and male
genital tumours (5th edition) has significantly improved our understanding of the …

[HTML][HTML] New developments in existing WHO entities and evolving molecular concepts: The Genitourinary Pathology Society (GUPS) update on renal neoplasia

K Trpkov, O Hes, SR Williamson, AJ Adeniran… - Modern Pathology, 2021‏ - Elsevier
Abstract The Genitourinary Pathology Society (GUPS) reviewed recent advances in renal
neoplasia, particularly post-2016 World Health Organization (WHO) classification, to provide …

The CLIP1–LTK fusion is an oncogenic driver in non‐small‐cell lung cancer

H Izumi, S Matsumoto, J Liu, K Tanaka, S Mori… - Nature, 2021‏ - nature.com
Lung cancer is one of the most aggressive tumour types. Targeted therapies stratified by
oncogenic drivers have substantially improved therapeutic outcomes in patients with non …

[HTML][HTML] Clinicopathologic features of kinase fusion-related thyroid carcinomas: an integrative analysis with molecular characterization

YH Chu, LJ Wirth, AA Farahani, V Nosé, WC Faquin… - Modern Pathology, 2020‏ - Elsevier
The discovery of actionable kinase gene rearrangements has revolutionized the therapeutic
landscape of thyroid carcinomas. Unsolved challenges include histopathologic recognition …

Translocation carcinomas of the kidney

P Argani - Genes, Chromosomes and Cancer, 2022‏ - Wiley Online Library
The MiT subfamily of transcription factors includes TFE3, TFEB, TFEC, and MITF. Gene
fusions involving two of these transcription factors have been well‐characterized in renal cell …

French AFU Cancer committee guidelines-update 2022-2024: management of kidney cancer

P Bigot, P Barthelemy, R Boissier, ZE Khene… - Progrès en Urologie, 2022‏ - Elsevier
Aim To update the recommendations for the management of kidney cancers. Methods A
systematic review of the literature was conducted from 2015 to 2022. The most relevant …

Towards a new WHO classification of renal cell tumor: What the clinician needs to know—A narrative review

A Cimadamore, L Cheng, M Scarpelli… - Translational …, 2021‏ - pmc.ncbi.nlm.nih.gov
In 1952, renal cell carcinomas had been divided into 2 categories—clear cell or granular cell—
depending upon their cytoplasmic staining characteristics. In the following years, the …

[HTML][HTML] Expanding the clinicopathological spectrum of succinate dehydrogenase-deficient renal cell carcinoma with a focus on variant morphologies: a study of 62 …

TL Fuchs, F Maclean, J Turchini, AC Vargas… - Modern Pathology, 2022‏ - Elsevier
Most succinate dehydrogenase (SDH)-deficient renal cell carcinomas (RCCs) demonstrate
stereotypical morphology characterized by bland eosinophilic cells with frequent …

Systemic therapies for the management of non–clear cell renal cell carcinoma: what works, what Doesn't, and what the future holds

P Zoumpourlis, G Genovese, NM Tannir… - Clinical genitourinary …, 2021‏ - Elsevier
Non–clear cell renal cell carcinoma (nccRCC) is a broad term that refers to a diverse group
of tumors, each with its own distinct biologic and therapeutic profile. The management of …